Despite the strong association between diabetes and dementia, how insulin deficiency affects brain function remains unclear. A recent study published in The FASEB Journal used a mouse model to investigate this mechanism.
First, researchers induced diabetes in a group of mice by administering streptozotocin, an agent that is destructive to insulin-producing cells. They then gave the diabetic mice insulin treatments to bring their blood glucose levels close to those of non-diabetic mice. After stabilizing the body weight and blood glucose levels of the diabetic mice, the researchers withdrew the insulin treatment.
The researchers observed a decline in the production of mitochondrial adenosine triphosphate (ATP) -- critical for all cellular functions -- in cortical regions of the brain that are associated with memory. The decline in ATP production mirrored previous studies examining insulin deficiency in the skeletal muscle of mice.
The team then administered intranasal insulin treatment to a group of non-diabetic mice, which subsequently exhibited an increase in mitochondrial ATP production.
"Our study points to the critical role of insulin in maintaining brain mitochondrial function," stated K. Sreekumaran Nair, MD, PhD, a consultant in endocrinology and professor of medicine at the Mayo Clinic. "Future human studies should explore how insulin treatment could reduce dementia and Alzheimer's disease among the millions of people living with diabetes."
Interestingly, unlike skeletal muscle and other organs in the body, the brain did not demonstrate an increase in reactive oxygen species (ROS) emission or oxidative stress. This finding suggests that, in the absence of insulin, the brain is uniquely protected from oxidative damage by enhancing anti-oxidant buffers that prevent the rapid decline of energy metabolism and cellular functions.
"Few would have anticipated these findings as regards the brain being within this overall energy balance sheet; not a frank intrusion like local hypoxia or a block in cerebral vasculature, but rather a more nuanced impact," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal.
###
This research was supported by the National Institute on Aging, the Mayo Clinic, the American Diabetes Association, the Indian Council of Medical Research, and the David H. Murdock-Dole Food Company Professorship.
The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. Receive monthly highlights for The FASEB Journal; subscribe at http://www.faseb.org/fjupdate.aspx.
FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to our societies and their members.
Journal
The FASEB Journal